Logotipo do repositório
 

Publicação:
Amyloid Fibrils Enhance the Topical Bio-Adhesivity of Liquid Crystalline Mesophase-Based Drug Formulations

dc.contributor.authorVictorelli, Francesca Damiani
dc.contributor.authorRodero, Camila Fernanda [UNESP]
dc.contributor.authorLutz-Bueno, Viviane
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.authorMezzenga, Raffaele
dc.contributor.institutionETH Zurich
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionPaul Scherrer Institute (PSI)
dc.date.accessioned2023-07-29T16:04:59Z
dc.date.available2023-07-29T16:04:59Z
dc.date.issued2023-05-08
dc.description.abstractDespite their distinctive secondary structure based on cross β-strands, amyloid fibrils (AF) are stable fibrous protein aggregates with features similar to collagen, one of the main components of the extracellular matrix, and thus constitute a potential scaffold for enhancing cell adhesion for topical applications. Here, the contribution of AF to skin bio-adhesivity aiming toward topical treatments is investigated. Liquid crystalline mesophase (LCM) based on phytantriol is formulated, with the aqueous phase containing either water or a solution of 4 wt% amyloid fibrils. Then resveratrol is added as a model anti-inflammatory molecule. The developed LCM presents a double gyroid Ia3d mesophase. The incorporation of AF into the LCM increases its bio-adhesive properties. In vitro release and ex vivo permeation and retention confirm the controlled release property of the system, and that resveratrol is retained in epidermis and dermis, but is also permeated through the skin. All formulations are biocompatible with L929 cells. The in vivo assay confirms that systems with AF lead to a higher anti-inflammatory effect of resveratrol. These results confirm the hypothesis that the incorporation of AF in the LCM increases the bio-adhesiveness and efficiency of the system for topical treatment, and consequently, the therapeutical action of the encapsulated drug.en
dc.description.affiliationDepartment of Health Sciences & Technology ETH Zurich
dc.description.affiliationDepartment of Drugs and Medicine School of Pharmaceutical Sciences São Paulo State University, São Paulo
dc.description.affiliationPaul Scherrer Institute (PSI)
dc.description.affiliationDepartment of Materials ETH Zurich
dc.description.affiliationUnespDepartment of Drugs and Medicine School of Pharmaceutical Sciences São Paulo State University, São Paulo
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2017/22758-3
dc.identifierhttp://dx.doi.org/10.1002/adhm.202202720
dc.identifier.citationAdvanced Healthcare Materials, v. 12, n. 12, 2023.
dc.identifier.doi10.1002/adhm.202202720
dc.identifier.issn2192-2659
dc.identifier.issn2192-2640
dc.identifier.scopus2-s2.0-85147411842
dc.identifier.urihttp://hdl.handle.net/11449/249633
dc.language.isoeng
dc.relation.ispartofAdvanced Healthcare Materials
dc.sourceScopus
dc.subjectamyloid fibrils
dc.subjectbio-adhesiveness
dc.subjectinflammatory diseases
dc.subjectliquid crystalline mesophases
dc.subjecttopical treatments
dc.titleAmyloid Fibrils Enhance the Topical Bio-Adhesivity of Liquid Crystalline Mesophase-Based Drug Formulationsen
dc.typeArtigopt
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
unesp.author.orcid0000-0002-7573-4514[1]
unesp.author.orcid0000-0002-3429-3513[2]
unesp.author.orcid0000-0001-9735-5470[3]
unesp.author.orcid0000-0002-6698-0545[4]
unesp.author.orcid0000-0002-5739-2610[5]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos